InsidersTradesSigma
Unicycive Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Unicycive Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the authority of SEC (Form 4). Operating in the Health Care sector, Unicycive Therapeutics, Inc. has recorded 10 reports. Market capitalisation: €220m. The latest transaction was disclosed on 1 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Aggarwal Gaurav. All data is openly available.
10
Insider Decl.
0
Thresholds
€11,855
1 ops.
Buy Volume
·
0 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Unicycive Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$40.99.
29Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations10 total
1,789,916 shares@ US$5.28CommonSEC144:0001178937-26-000032
652,900 sharesCommon StockSEC:0001213900-25-080808:0
1,400,000 sharesCommon StockSEC:0001213900-25-015152:0
5,500,000 sharesCommon StockSEC:0001213900-24-086928:0
3,470,152 sharesCommon StockSEC:0001213900-23-056885:0
104,612 sharesCommon StockSEC:0001213900-23-056875:0
104,612 sharesCommon StockSEC:0001213900-23-056848:0
41,845 sharesCommon StockSEC:0001213900-23-056864:0
26,738 shares0Common StockSEC:0001213900-22-052329:0
15,000 shares@ US$0.8250.0054% mcap100.0% of flowCommon StockSEC:0001213900-22-027501:0
Ideal exit: 10 Feb 2023 (T+270)
10 of 10 declarations
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for kidney diseases. It is listed on NASDAQ under the ticker symbol UNCY.